Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia

Treatment with zanubrutinib resulted in a higher combined complete response and very good partial response rate than therapy with ibrutinib in patients with Waldenström macroglobulinemia. Dr. Tam shares updated data from the phase III ASPEN trial.